The DOI matches its Crossref record.
Ligand-Targeted Liposomes for Cancer Treatment
Abstract
Selective targeting of ligand-targeted liposomes containing anticancer drugs or therapeutic genes to cell surface receptors expressed on cancer cells is a recognized strategy for improving the therapeutic effectiveness of conventional chemotherapeutics or gene therapeutics. Some recent advances in the field of ligand-targeted liposomes for the treatment of cancer are summarized including: selection criteria for the receptors to be targeted, choice of targeting ligands and choice of encapsulated therapeutics. Targeting of liposomes to solid tumors, versus angiogenic endothelial cells versus vascular targets is discussed. Ligand-targeted liposomes have shown considerable promise in preclinical xenograft models and are poised for clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Self-citationPharmacokinetics and Biodistribution of Nanoparticles
Li, S.-D., & Huang, L. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800049w · Cited by 1,568
Liposomes: Structure, composition, types, and clinical applications
Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09394 · Cited by 1,561
Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Puri, A., Loomis, K., Smith, B., Lee, J.-H., Yavlovich, A., Heldman, E., & Blumenthal, R. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,069
Nanoparticles: pharmacological and toxicological significance
Medina, C., Santos‐Martinez, M. J., Radomski, A., Corrigan, O. I., & Radomski, M. W. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707130 · Cited by 738
Application of Nanotechnology in Cancer Therapy and Imaging
Wang, X., Yang, L., Chen, Z., & Shin, D. M. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0003 · Cited by 700
Nanooncology: The future of cancer diagnosis and therapy
Thakor, A. S., & Gambhir, S. S. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21199 · Cited by 588
Nanotoxicity: An Interplay of Oxidative Stress, Inflammation and Cell Death
Khanna, P., Ong, C., Bay, B., & Baeg, G. (2015) · Nanomaterials · doi:10.3390/nano5031163 · Cited by 580
Advances and challenges in smart and functional polymer vesicles
Du, J., & O'Reilly, R. K. (2009) · Soft Matter · doi:10.1039/b905635a · Cited by 572
Shen, Y., Jin, E., Zhang, B., Murphy, C. J., Sui, M., Zhao, J., Wang, J., Tang, J., Fan, M., Van Kirk, E., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja909475m · Cited by 565
Overcoming barriers by local drug delivery with liposomes
Antimisiaris, S. G., Marazioti, A., Kannavou, M., Natsaridis, E., Gkartziou, F., Kogkos, G., & Mourtas, S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.019 · Cited by 339
Fernandez-Fernandez, A., Manchanda, R., & McGoron, A. J. (2011) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-011-9383-z · Cited by 330
Progress, challenges, and future of nanomedicine
Zhang, C., Yan, L., Wang, X., Zhu, S., Chen, C., Gu, Z., & Zhao, Y. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101008 · Cited by 318
Charge‐Reversal Drug Conjugate for Targeted Cancer Cell Nuclear Drug Delivery
Zhou, Z., Shen, Y., Tang, J., Fan, M., Van Kirk, E. A., Murdoch, W. J., & Radosz, M. (2009) · Advanced Functional Materials · doi:10.1002/adfm.200900825 · Cited by 311
Nanomedicine applied to translational oncology: A future perspective on cancer treatment
Bregoli, L., Movia, D., Gavigan-Imedio, J. D., Lysaght, J., Reynolds, J., & Prina-Mello, A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.08.006 · Cited by 296
Belfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.040 · Cited by 294
Pros and Cons of the Liposome Platform in Cancer Drug Targeting
Gabizon, A. A., Shmeeda, H., & Zalipsky, S. (2006) · Journal of Liposome Research · doi:10.1080/08982100600848769 · Cited by 272
Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy
Rommasi, F., & Esfandiari, N. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03553-8 · Cited by 269
Organelle targeting: third level of drug targeting
Padh, H., & Sakhrani, N. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s45614 · Cited by 269
Fenske, D. B., & Cullis, P. R. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.1.25 · Cited by 253
Lipid-based nanoparticle formulations for small molecules and RNA drugs
Ickenstein, L. M., & Garidel, P. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1669558 · Cited by 193
Bulitta, J. B., Zhao, P., Arnold, R. D., Kessler, D. R., Daifuku, R., Pratt, J., Luciano, G., Hanauske, A.-R., Gelderblom, H., Awada, A., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0827-2 · Cited by 47
Metadata
- Authors
- Sapra, P., Tyagi, P., & Allen, T.
- Venue
- Current Drug Delivery
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-10-01
- Volume
- 2
- Issue
- 4
- Pages
- 369-381
- ISSN
- 1567-2018 (ISSN-L)
- OpenAlex
- W2152854631
- Cited by
- 246
- References
- 0
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.